Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Below-Study
NCT00163254Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2003
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abciximab in peripheral artery disease (PAD) (4 arms), sponsored by University Hospital Tübingen. Primary endpoint: Rate of subacute reocclusions at 60 days. Status: unknown.
02
Drugs
abciximab
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT00163254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163254.